Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $526.96, generating $5.01 million. Her remaining stake totaled 324,443 shares, worth approximately $171.0 million.
- United Therapeutics reported quarterly EPS of $7.27, exceeding analyst expectations of $6.86, while revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
- Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $646; institutional investors own 94.08% of the company’s shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Trading Down 1.5%
United Therapeutics stock opened at $521.00 on Friday. The firm has a market capitalization of $22.35 billion, a P/E ratio of 18.64, a P/E/G ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The stock's fifty day simple moving average is $533.74 and its 200-day simple moving average is $537.53.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the business posted $6.41 earnings per share. United Therapeutics's revenue was down 1.9% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Arjuna Capital increased its holdings in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after buying an additional 18 shares in the last quarter. Sage Rhino Capital LLC raised its position in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC grew its holdings in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. raised its holdings in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after buying an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance lifted its position in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts recently commented on UTHR shares. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Weiss Ratings raised United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, August 13th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Finally, Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $646.00.
View Our Latest Research Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
